Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients

被引：42

作者：

Shen, Yong ^{[1
,2
]}

Zhang, Suzhan ^{[1
,2
]}

Sun, Ren ^{[1
,2
,3
]}

Wu, Tingting ^{[1
,2
,3
]}

Qian, Jing ^{[2
,4
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Inst Canc,China Natl Minist Educ,Key Lab Canc Pre, Hangzhou 310009, Zhejiang, Peoples R China

[2] Zhejiang Univ, Sch Med, Collaborat Innovat Ctr Diag & Treatment Infect Di, ZJU UCLA Joint Ctr Med Educ & Res, Hangzhou 310058, Zhejiang, Peoples R China

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

[4] Zhejiang Univ, Sch Med, Res Ctr Infect & Immun, Hangzhou 310058, Zhejiang, Peoples R China

来源：

EMERGING MICROBES & INFECTIONS | 2015年 / 4卷

基金：

中国国家自然科学基金;

关键词：

adaptive immunity; EBV; immune evasion; innate immunity; NPC; NASOPHARYNGEAL CARCINOMA-CELLS; REGULATORY T-CELLS; MEMBRANE-PROTEIN; NF-KAPPA-B; ANTIGEN-PROCESSING FUNCTION; BURKITTS-LYMPHOMA CELLS; CLASS-II EXPRESSION; COMPLEX CLASS-I; DENDRITIC CELLS; LATENT MEMBRANE-PROTEIN-1;

D O I：

10.1038/emi.2015.20

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Epstein-Barr virus (EBV) has been used as a paradigm for studying host-virus interactions, not only because of its importance as a human oncogenic virus associated with several malignancies including nasopharyngeal carcinoma (NPC) but also owing to its sophisticated strategies to subvert the host antiviral responses. An understanding of the interplay between EBV and NPC is critical for the development of EBV-targeted immunotherapy. Here, we summarize the current knowledge regarding the host immune responses and EBV immune evasion mechanisms in the context of NPC.

引用

页数：9

共 50 条

[31] Epstein-Barr Virus
Jenson, Hal B.
PEDIATRICS IN REVIEW, 2011, 32 (09) : 375 - 384
[32] Epstein-Barr virus
Rickinson, A
VIRUS RESEARCH, 2002, 82 (1-2) : 109 - 113
[33] THE RELATIONSHIP BETWEEN EPSTEIN-BARR VIRUS AND LYMPHOMA
BIRD, AG
BRITTON, S
SEMINARS IN HEMATOLOGY, 1982, 19 (04) : 285 - 300
[34] DEFECTIVE IMMUNITY TO EPSTEIN-BARR VIRUS IN ANKYLOSING-SPONDYLITIS
ROBINSON, S
PANAYI, GS
BRITISH JOURNAL OF RHEUMATOLOGY, 1985, 24 (01): : 87 - 87
[35] Mitophagy: a strategy of the Epstein-Barr virus to evade innate immunity
Glon, Damien
Lussignol, Marion
Esclatine, Audrey
M S-MEDECINE SCIENCES, 2020, 36 (11): : 990 - +
[36] Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes
Savard, Martin
Gosselin, Jean
VIRUS RESEARCH, 2006, 119 (02) : 134 - 145
[37] Epstein-Barr virus: The virus and its tumorigenicity in the normal and immunocompromised host
RaabTraub, N
BAILLIERES CLINICAL INFECTIOUS DISEASES, 1996, 3 (03): : 457 - 475
[38] The biology of Epstein-Barr virus: lessons learned from the virus and the host
Cohen, JI
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (04) : 365 - 370
[39] Epstein-Barr virus in patients with persistent lymphadenopathy
Melikyan, A. L.
Garanzha, T. A.
Tikhomirov, D. S.
Kaplanskaya, I. B.
Varlamova, E. Yu
Kovalyova, L. G.
Filatov, F. P.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2007, 52 (04): : 21 - 27
[40] Epstein-Barr virus Infections in the Immunosuppressed Patients
Yavuz, Gulsan
JOURNAL OF PEDIATRIC INFECTION, 2009, 3 : 17 - 21

← 1 2 3 4 5 →